GSKGLAXF 69 Equity-to-Asset is 0.28 as of Mar. 2026, which is 56% above its 10-year median of 0.18. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.85 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,008 Drug Manufacturers companies, GSK ranks worse than 84.42% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. GSK's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $23,803 Mil. GSK's Total Assets for the quarter that ended in Mar. 2026 was $83,825 Mil.
Therefore, GSK's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.28.
The historical rank and industry rank for GSK's Equity-to-Asset or its related term are showing as below:
GLAXF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0 Med: 0.18 Max: 0.28
Current: 0.28
During the past 13 years, the highest Equity to Asset Ratio of GSK was 0.28. The lowest was 0.00. And the median was 0.18.
GLAXF's Equity-to-Asset is ranked worse than 84.42% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs GLAXF: 0.28
GSK (OTCPK:GLAXF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
GSK Equity-to-Asset Related Terms
GSK Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for GSK's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLAXF vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, GSK's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where GSK's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
GSK's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (GLAXF) has a Equity-to-Asset of 0.28 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on GSK and its competitors. This is 56% above median its historical median of 0.18. According to the industry distribution chart, GSK ranks #851 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 84.4%.
Is GSK's Equity-to-Asset too high?
GSK's current Equity-to-Asset of 0.28 is 56% above median its 10-year median of 0.18. The Drug Manufacturers industry median Equity-to-Asset is 0.61. GSK's value of 0.28 is 54.1% below this industry median. Based on the distribution chart, GSK ranks #851 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #851 out of 1008 companies for Equity-to-Asset. This places GSK in the lower half of its industry. The industry median Equity-to-Asset is 0.61. GSK's value of 0.28 is 54.1% below this benchmark. While the company's 10-year median is 0.18 vs. the industry median of 0.61, GSK has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Equity-to-Asset of 0.28 is 54.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Equity-to-Asset is 0.28, which is 56% above median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.85, compared to a current price of $26.29 — trading 20.3% above its estimated fair value. The current Equity-to-Asset is 0.28, which is 56% above median its 10-year median of 0.18 and 54.1% below the Drug Manufacturers industry median of 0.61. GSK's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For GSK (GLAXF), the current Equity-to-Asset is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $26.29 is trading 20.3% above its estimated GF Value™ of $21.85.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
Equity-to-Asset: 0.28 (56% above median its 10-year median of 0.18)
GF Value™: $21.85 vs. price of $26.29 (20.3% above fair value)
Industry Position: 54.1% below the Drug Manufacturers median (#851 of 1008)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score
Get the complete analysis for GLAXF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
